The deal transforms Jupiter's pipeline and narrative, likely driving near-term speculative interest given the small market cap and regulatory tailwinds. However, the stock component of the upfront creates dilution, and the company must finance development milestones. Monitor for financing announcements and clinical trial initiation timelines for ALA-002.
Price Chart
Executive Summary
Jupiter Neurosciences licensed exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity (non-racemic MDMA) from PharmAla Biotech, in a deal valued up to $100M including milestones and a 3% royalty. The $3.3M upfront ($1.5M cash + $1.8M stock) transforms Jupiter from a single-asset Parkinson's company into a dual clinical-stage CNS developer, leveraging a favorable regulatory executive order. For an $8M market-cap company, the deal is transformative but carries substantial execution risk and dilution from the stock component.
Key Financial Metrics
Key Facts
- Jupiter licensed perpetual exclusive U.S. rights to ALA-002, an FDA NCE-designated non-racemic MDMA for PTSD and neuropsychiatric conditions.
- Total deal value up to $100M including milestones: $3.3M upfront ($1.5M cash + $1.8M stock with 120-day lock-up), $3.3M Phase 3 FPI milestone, $20M NDA approval milestone, and commercial milestones at $333M/$1B/$2B cumulative net sales.
- Jupiter pays a 3% royalty on net sales after the third commercialization milestone.
- ALA-002 targets a U.S. psychedelic therapeutics market estimated at $3B in 2024 growing to $8B by 2030.
- The deal leverages an April 18, 2026 Executive Order accelerating psychedelic therapy access, including Right to Try and expedited FDA review.
- Jupiter's market cap is ~$8M; the upfront stock component (~22.5% of current cap) creates dilution risk.
Financial Impact
Up to $100M in milestone payments plus 3% royalty on net sales; $3.3M upfront ($1.5M cash + $1.8M stock).
Risk Factors
- Jupiter must fund development milestones and clinical trials; additional dilutive financing is likely given $8M market cap.
- ALA-002 is early-stage (pre-Phase 1) with no clinical data; safety/efficacy risks are high.
- DEA scheduling and regulatory pathway for MDMA-based therapies remain uncertain despite the Executive Order.
- PharmAla retains rights outside the U.S., limiting total addressable market for Jupiter.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13G/A | $2.88 | awaiting T+5 | — | $2.86 (−0.69%) |
Sep 24, 2026 4w ago | S-3 | $2.67 $2.55 | ▲ +4.49% | ▲ +4.27% | $2.86 (−7.12%) |
Sep 22, 2026 5w ago | SC 13G | $2.98 $2.58 | ▼ −13.42% | ▼ −12.24% | $2.86 (−4.03%) |
Aug 28, 2026 8w ago | 8-K | $3.54 $3.08 | ▲ +12.99% | ▲ +12.85% | $2.86 (+19.21%) |
Aug 27, 2026 8w ago | 8-K | $4.89 $3.26 | ▲ +33.33% | ▲ +33.60% | $2.86 (+41.51%) |
Aug 24, 2026 9w ago | 8-K | $5.17 $3.35 | ▲ +35.20% | ▲ +34.66% | $2.86 (+44.68%) |
Aug 24, 2026 9w ago | 8-K | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Aug 24, 2026 9w ago | 424B5 | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Jul 27, 2026 13w ago | 8-K | $0.1135 $0.1000 | ▲ +11.89% | ▲ +14.41% | $2.86 (−2419.82%) |
Jul 21, 2026 14w ago | Press Release | $0.1697 $0.1097 | ▼ −35.36% | ▼ −34.36% | $2.86 (+1585.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers